Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune Inc., Micromet AG deal

Under a co-development deal, Micromet granted MEDI North American development rights to its MT103 bispecific T cell engager (BiTE) to treat non-Hodgkin's

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE